Fluorination has gained an increasingly important role in drug discovery and development. Here we describe a versatile strategy that combines cytochrome P450-catalyzed oxygenation with deoxofluorination to achieve mono-and polyfluorination of nonreactive sites in a variety of organic scaffolds. This procedure was applied for the rapid identification of fluorinated drug derivatives with enhanced membrane permeability.
Fluorination has become an increasingly important tool for finetuning the pharmacokinetic and pharmacological properties of drugs and lead compounds, thus leading to a growing number of fluorinecontaining pharmaceuticals on the market 1 . Benefits of hydrogento-fluorine substitutions arise principally from their effects on membrane permeability, metabolic stability and/or receptor-binding properties of bioactive molecules [1] [2] [3] . In many cases, fluorination of much less active precursors has yielded potent drugs with enhanced bioavailability, reduced toxicity or improved affinity for the target receptor 3 . A number of methods have been developed for synthesis of fluorinated compounds 4, 5 , including asymmetric fluorination strategies 6, 7 and chemo-enzymatic approaches 8, 9 . Despite this progress, selective incorporation of fluorine at non-activated or weakly reactive sites of a target scaffold remains difficult and may require several synthetic steps.
Here we describe a facile two-step procedure for the selective fluorination of one or more non-activated sites in an organic molecule. This approach couples the exceptional ability of cytochrome P450 monooxygenases to selectively insert oxygen into nonreactive C-H bonds with a deoxofluorination reaction in which the newly generated hydroxyl group is substituted by fluorine by means of a nucleophilic fluorinating reagent (Fig. 1) . To test the validity of this approach, we targeted various classes of small molecules, including marketed pharmaceuticals ( Supplementary Fig. 1 online) . For the enzymatic step, we used variants of the bacterial long-chain fatty acid hydroxylase P450 BM3 from Bacillus megaterium. Catalytic self-sufficiency, high monooxygenase activity and high expression level in Escherichia coli render P450 BM3 an attractive catalyst for in vitro and in vivo applications 10 . For this work, we assembled a panel of 96 P450s derived from a catalytically promiscuous P450 BM3 variant identified in the early stages of the directed evolution of a proficient alkane monoxygenase 11 . These variants were found to exhibit good activity and various degrees of selectivity on alkanes and non-alkane substrates 11 .
The first group of test molecules (1, 2 and 3; Fig. 2a,b) contain a cyclopentenone moiety found in several natural products (for example, jasmonoids, cyclopentanoid antibiotics and prostaglandins). The synthesis and functionalization of these scaffolds is not trivial 12 . The activities of the enzymes toward these substrates were probed in multiwell format using gas chromatography and GC-MS (Fig. 2a) . Depending on the substrate, approximately 30 to 50% of the 96 enzyme variants displayed useful activity (4800 turnovers), while 30 to 50% of this active subset showed moderate to excellent regioselectivity (50-100%). The most active and selective variants were applied in preparative scale reactions (100-300 mg) using B0.05 mol% catalyst. Compared with 96-well plate reactions, three to four times higher turnover numbers could be obtained using purified enzyme and longer reaction times (24-48 h). After flash chromatography purification, the hydroxylated products were subjected to deoxofluorination using the common nucleophilic fluorinating agent diethylaminosulfur trifluoride (DAST, 4). The identities and purities of the fluorinated products were established by GC-MS, HRMS and 1 H, 13 C and 19 F NMR (Supplementary Methods online). Using this strategy, we were able to target two to three different sites on each substrate with good to excellent regioselectivity (55-100%), thereby affording the fluorinated derivatives 5, 6, 7, 8, 9, 10 and 11 with yields of up to 80% over the two steps.
Next we tested this fluorination strategy on a methylester pro-drug of the anti-inflammatory drug ibuprofen (12; Fig. 2a,c) . Although preparation of a-fluoro derivatives of this compound is straightforward 13 , incorporating fluorine atoms in the poorly reactive isobutyl group is not. The general procedure described above enabled us to identify two chemo-enzymatic routes to achieve this goal in a selective (position 1, 75%; position 2, 100%) and efficient manner (yields over two steps for 15 and 16 were 62% and 84%, respectively) and at preparative scales (150-200 mg). We then investigated whether two sequential chemo-enzymatic transformations could be used to fluorinate multiple sites of the same molecule. P450 variant B4 (var-B4)-which was used to convert 12 to 13-was found to retain comparable activity on 16, providing a possible route to the desired 17 intermediate. Re-screening of 12-active variants on 16, however, led to the identification of a more suitable candidate, var-B2, with higher activity than var-B4 toward 16 and excellent (100%) 2-regioselectivity. Using var-B2, the synthesis of fluorohydroxy derivative 17 was afforded in higher yields (93% versus 72% for conversion of 12 to 13) and required less catalyst (0.06 mol% versus 0.1 mol% for conversion of 12 to 13). 17 was then converted quantitatively to the desired difluoroderivative 18.
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The value of the present approach as synthetic tool for asymmetric fluorination was also examined. In the absence of anchimeric group participation, the deoxofluorination reaction generally preserves the enantiopurity of the enzymatic products through inversion of configuration 14 . Chiral gas chromatography analysis showed appreciable stereoselectivity during preparation of 7 (78% enantiomeric excess (ee), 9 (diasteromeric ratio (dr) 1:8.5), 10 (dr 4:96), 15 (dr 1:3.2) and 18 (dr 1:3.7) (see Supplementary Figs. 2-6 online for gas chromatography traces). We then extended our previous investigations on 2-phenylacetic acid esters 15 , carrying out the asymmetric synthesis of the corresponding 2-fluoro-2-arylacetic acid derivatives at 100-mg scale (19a, 20a, 21a, 22a and 23a; Supplementary Table 1 online). In this case, up to 89% ee in up to 60% yield (two steps) was achieved.
P450-catalyzed hydroxylation of methoxy groups leads to exposure of a free hydroxyl group through decomposition of the hemi-acetal produced and release of formaldehyde. We reasoned that our chemoenzymatic strategy could be extended to substitute a methoxy group for fluorine, a challenging transformation for traditional chemical methods. This approach was first tested on the 5-phenyloxazoline derivative 24 (Fig. 3a,b) . The demethylation activities of the P450 variants could be easily assessed using a colorimetric screen (Fig. 3a) . The most active variants from the screen were further analyzed with respect to the regioselectivity of oxidation using GC-MS. The highly selective P450 variant var-H1 (95%) was thus applied in combination with deoxofluorination to afford the desired fluorine-containing compound (26).
The same approach was tested on a set of derivatives of the synthetically important building block Corey lactone (Fig. 3c) . The use of various Corey lactones (27a, 28a and 29a) enabled us to investigate the tolerance of the enzymatic transformation to structural variations within the target scaffold. Based on the colorimetric screen, 30 variants displayed activity on at least one Corey lactone (12 on 27a, 17 on 28a, 5 on 29a). Twelve variants were found to accept both 27a and 28a, five were found to accept 28a and 29a and five were found to accept 27a and 29a. Notably, four variants (B10% of the Corey lactone-active variants) could be used to activate the substrate for subsequent fluorination, regardless of the size of the variable substituent. Using the most active and selective enzymes toward each of the Corey lactones, the desired fluorine-containing compounds 27c, 28c and 29c were synthesized and isolated. Ibuprofen has recently shown promising activity against amyloidogenic diseases 16 . Anti-amyloidogenic drugs with high brain permeability are intensively sought 16 . We tested 15, 16 and 18 in a membrane permeability assay that mimics the composition of the blood brain barrier (BBB). While 12 has only modest BBB-crossing potential, monofluorinated 15 and 16 and difluorinated 18 exhibit, respectively, very good and excellent membrane permeability properties (effective permeability value 4 10 Â 10 À6 cm s -1 ; Supplementary Fig. 7 online), which demonstrates how this procedure could be applied to rapidly screen various hydrogen-to-fluorine substitutions in a target molecule for improvement in chemophysical or biological properties.
This chemo-enzymatic approach has proven useful for fluorinating 13 of the 16 molecules tested (see Supplementary Fig. 1 ). The molecular weight of these compounds ranges between 110 and 450 Da. About 75% of commercial drugs fall within this window 17 . Much larger molecules may have restricted access to the enzyme's active site, representing suboptimal targets for this chemo-enzymatic approach. As the P450 BM3 active site is largely hydrophobic, highly polar compounds may also be poor substrates. Difficulties were mostly associated with solubilization of the substrate in aqueous media (30) or with the occurrence of side reactions-in particular eliminationduring the deoxofluorination transformation (hydroxylated 31 and 32), which prevented isolation of the enzymatic and fluorinated products, respectively, in satisfactory yields. These issues could be addressed, however, by using P450 BM3 variants with increased activity in the presence of organic co-solvent 18 and applying milder nucleophilic fluorination methods.
Overall, the described methodology extends the range of available tools for selective fluorination. Importantly, it provides a concise solution to selective incorporation of fluorine atoms at relatively unreactive sites in a variety of organic molecules and at a preparative scale. The regio-and stereoselectivity of this chemical transformation can be altered by engineering the protein catalyst. This strategy is versatile, as the same chemo-enzymatic route can be applied to various structurally related scaffolds, and more chemo-enzymatic transformations can be combined for selective fluorination of multiple sites on the same molecule. A common strategy for improving drugs' in vivo half-lives involves blocking the sites in the molecule that are susceptible to attack by human P450s with fluorine substituents 2, 3 . It is worth noting that fluorination of position 2 in 15 and 18 would prevent one of the major P450-dependent routes of ibuprofen metabolism in humans 19 . An added advantage of this approach is thus to enable fluorination of metabolically vulnerable sites in the target molecule. We expect this procedure to find utility in the rapid identification of drug or lead compound derivatives with improved chemophysical or biological properties and in the preparation of fluorinated synthons for chemical synthesis or fragment-based drug discovery programs.
Note: Supplementary information and chemical compound information is available on the Nature Chemical Biology website. Membrane permeability properties of 12 and its fluorinated derivatives. Supplementary Table 1 Stereoselective fluorination of substituted 2-aryl acetic acid esters. mol% Yield (i) [b] Yield (ii)
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[a] The sequences of the P450 variants are reported in Supplementary V78A, H138Y, T175I, V178I, A184V, H236Q, E252G, R255S, A290V, A295T, L353V
var-B3
[b]
R47C, V78A, K94I, P142S,T175I, A184V, F205C, S226R, H236Q, E252G, R255S, A290V, L353V
var-B4 F87A
var-C12
[c]
R47C, V78A, F87A, K94I, P142S,T175I, A184V, F205C, S226R, H236Q, E252G, R255S, A290V, L353V
var-D10
R47C, V78A, A82L, K94I, P142S,T175I, A184V, F205C, S226R, H236Q, E252G, R255S, A290V, A328V, L353V
var-G4
V78A, A82G, F87V, P142S,T175I, A184V, F205C, S226R, H236Q, E252G, R255S, A290V, A328V, L353V
var-G5
V78A, F87I, P142S,T175I, A184V, F205C, S226R, H236Q, E252G, R255S, A290V, L353V
var-G6
V78A, F81P, A82L, F87A, P142S, T175I, A180T, A184V, A197V, F205C, S226R, H236Q, E252G, R255S, A290V, L353V
R47C, L52I, V78F, A82S, K94I, P142S,T175I, A184V, F205C, S226R, H236Q, E252G, R255S, A290V, A328L, K349N, L353V, I366V, E464G, I710T
var-H3
[a]
V78A, T175I, A184V, F205C, S226R, H236Q, E252G, R255S, A290V, L353V
[a] var-B2 and var-H3 correspond, respectively, to variants 139-3 and J described in Fasan et al. 4 . [b] var-B3 corresponds to variant 9-10A described in Meinhold et al.
.
[c] These variants are derivatives of variant var-B3.
[d] var-H1 is a derivative of variant ETS8 described in Fasan et al.
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Materials, Methods and Synthetic Procedures
Reagents and Analytical Methods. Chemical reagents, substrates and solvents were purchased from Sigma-Aldrich, Acros Organics, Fluka, and Kaironkem. Silica gel chromatography purifications were carried out using AMD Silica Gel 60 230-400 mesh.
Gas chromatography (GC) analyses were carried out using a Shimadzu GC-17A gas chromatograph, a FID detector, and an Agilent HP5 column (30 m x 0.32 mm x 0.1 μm film). Chiral GC analyses were carried out using a Shimadzu GC-17A gas identified in the colorimetric screen were re-tested for selectivity towards demethylation. 1-mL scale reactions were carried out using 1 mM 24, 0.5 μM P450, 400
μM NADPH, 10 mM glucose-6-phosphate and 1 U/mL glucose-6-phosphate dehydrogenase. After stirring for 16 hours at room temperature, the reaction mixtures were extracted with chloroform and analyzed by GC-MS on a Hewlett-Packard 5970B
MSD with 5890 GC using a DB-5 capillary column, 1 μL injection, 250 °C inlet, and the following separation program: 80 °C oven, 10 °C/min gradient to 250 °C, 250 °C for 3 min. Enzyme activity on 27a, 28a, and 29a was screened by mixing 50 μL cell lysate, 100 μL 100 mM KPi buffer (pH 8.0) containing 1 mM substrate (1% DMSO), and 50 μL 4 mM NADPH in microtiter plates. After 30 min, 50 μL 150 mM Purpald (Sigma) 11 in 2 M NaOH were added to each well. Absorbance at 550 nm was measured after 60 minutes. The most active variants were re-tested at 1-mL scale using 1 mM substrate, 0.5 μM purified P450, and the cofactor regeneration system described above. After overnight incubation at 4 °C, reactions were analyzed by HPLC-MS using an Agilent 1100 Series LC/MSD device and Kromasil 100, 5 μm-C 18 column.
Membrane permeability assay. The membrane permeability assays were carried out adapting a described procedure 2 and using 96-well MultiScreen-IP plates from
Millipore. Filter plates were rinsed with 70% EtOH and double-distilled water prior to use. BBB-mimic membranes were prepared by coating filter wells with 5 µL porcine brain lipids (PBL, Avanti Polar Lipids) in dodecane (20 mg/mL). Control wells (PBLfree) were primed in the same way but not coated with PBL. Working solutions contained 0.5 mg/mL fluorinated compound in PBS pH 7.4 (5% EtOH). Assembled plates contained 150 µL working solution in the PBL-coated (or PBL-free) well, 300 µL PBS (5% EtOH) in the acceptor well, and were incubated at room temperature and 100% humidity. The change in organic compound concentration in the donor and acceptor wells was monitored over time by HPLC. Membrane permeability values (P e )
were calculated as described. 3 All measurements were performed in triplicates. The assay was validated by comparing our experimental P e value for caffeine with that Chiral GC analyses were carried out using a Shimadzu GC-17A gas chromatograph, Conversion of 3 to 9. 230 mg (1.53 mmol) 3 were dissolved in 2 mL ethanol and added to 300 mL potassium phosphate buffer pH 8.0. The solution was added with var-D10 (final conc.: 2.5 μM) and a cofactor regeneration system (final conc.: 500 μM NADPH, 30 mM glucose-6-phosphate, 1 unit/mL glucose-6-phosphate dehydrogenase) and stirred at room temperature. After 48 hours, the reaction mixture was extracted with dichloromethane (4 x 80 mL). The combined organic phases were dried over anhydrous and stirred at room temperature. After 36 hours, the reaction mixture was extracted with dichloromethane (4 x 80 mL). The combined organic phases were dried over anhydrous Chiral GC analyses were carried out using a Shimadzu GC-17A gas chromatograph, and stirred at room temperature. After 48 hours, the reaction mixture was extracted with dichloromethane (4 x 70 mL). The combined organic phases were dried over anhydrous Conversion of 28a to 28c. To a solution containing potassium phosphate buffer pH 8.0 and 1 mM 28a in 1% DMSO was added with var-B3 (final conc.: 5 μM) and a cofactor regeneration system (final conc.: 500 μM NADPH, 30 mM glucose-6-phosphate, 2 units/mL glucose-6-phosphate dehydrogenase). The reaction was stirred for 48 hours at room temperature, then worked-up as described above. 
